Collaboration Eases Patient Access to Therapy LAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) —…
Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in…
– 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4…
NEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins…
Shockwave M5+ IVL Catheter Broadens Options for Treatment of Peripheral Arteries SANTA CLARA, Calif., March…
– First description of new, comprehensive anellovirus antibody analysis tool, AnelloScan – – Cross-sectional study supports…
ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity ISELIN,…
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform…
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian…
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality…
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued…
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial…
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)…
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid…
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP;…
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…